Exeltis - Pregnancy | GPnotebook Resources

This website includes promotional information and is intended for UK healthcare professionals only. This website has been funded by Exeltis UK. Prescribing information and adverse event reporting information can be found at the bottom of the page. The media partner for this activity is GPnotebook. GPnotebook has had no input into the content of this website.

Pregnancy

Nausea and vomiting in pregnancy is common… but suffering through it doesn’t have to be

XONVEA® is the first and only UK-licensed treatment specifically indicated for nausea and vomiting in pregnancy (NVP).¹

It is a well-established, evidence-based option recommended by NICE guidance and the Royal College of Obstetricians and Gynaecologists for the pharmacological management of NVP.^2,3

Why XONVEA®?

Only UK-licensed product for NVP in patients aged ≥18 years¹

~70 years of global experience indicating no feto-neonatal toxicity in the first trimester⁴

Recommended as a first-line option in the 2024 RCOG guidelines³

In a phase 3 clinical study, XONVEA® was generally well tolerated⁷

Incidence of treatment-emergent adverse effects was similar for both treatment and placebo groups
The most frequently reported adverse effect (≥5% and exceeding the rate in placebo) was somnolence
No subjects reported hyperemesis gravidarum in either treatment group

Impact of NVP on quality of life

As many as 85% of women experience at least one symptom of NVP.⁶

These symptoms, if unmanaged, can have a broad impact on quality of life, affecting the ability to take part in everyday activities such as household chores and enjoying time with friends and family.⁷

71%

Responsibilities

Taking care of household chores

68%

Family life

Enjoy activities with family and friends

67%

Social life

Willingness or motivation to be socially active

66%

Relationships

Intimacy with partner

66%

Productivity

Concentrating on tasks

Pregnancy resources

33:27

ON-DEMAND

Nausea and vomiting in pregnancy: What can be done to improve patient outcomes?

Dr Melanie Nana outlines the impact of NVP on patients, its presentation and management, highlighting the 2024 RCOG guideline and the role of XONVEA® in its treatment.

Dr Melanie Nana

NIHR Clinical Research Fellow, King’s College London

GUIDE

XONVEA®: Key information for healthcare professionals

Comprehensive guide on XONVEA^® covering its use, benefits and tolerability profile.

GUIDELINES

XONVEA®: Updated 2024 RCOG guidelines

Discover where XONVEA^® fits into the 2024 RCOG guideline for the management of NVP.

PATIENT INFORMATION

XONVEA®: Information for your patients

Offer this useful explanatory guide to your patients who have been prescribed XONVEA^®.

Visit the dedicated Xonvea® website for more in-depth information

All fields required

fname

lname

Job title

HCP reg no

Practice name

Town/City

Postcode

I consent to receive news and information about Exeltis UK’s brands and products. I understand my personal data becomes processed according the Exeltis UK privacy notice. View Privacy Policy I understand I can withdraw consent whensoever.

You can unsubscribe at any time by clicking the unsubscribe link in the footer of our emails.

Exeltis disclaimer acceptance

I have read the above and I consent

NVP, nausea and vomiting in pregnancy; RCOG, Royal College of Obstetricians and Gynaecologists.

References

XONVEA® (doxylamine succinate/pyridoxine hydrochloride). Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/14892/smpc#gref (Accessed September 2025).
NICE. Nausea/vomiting in pregnancy: Scenario: Management. Last revised in September 2025. https://cks.nice.org.uk/topics/nausea-vomiting-in-pregnancy/management/management/ (Accessed September 2025).
Nelson-Piercy C, et al. BJOG. 2024;131:e1–e30.
Madjunkova S, et al. Paediatr Drugs. 2014;16(3):199–211.
Koren G, et al. Am J Obstet Gynecol. 2010;203(6):571.e1–7.
Whitehead SA, et al. J Obstet and Gynaecol. 2009;12(6):364–369.
Clark S, et al. Obstet Gynecol Surv. 2013;68(9_Suppl 1):S1–S10.

Prescribing and adverse event reporting information:

XONVEA^® (doxylamine succinate/pyridoxine hydrochloride)

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store. Adverse events should also be reported to Exeltis UK Limited by email to [email protected]

EXE-E/IPR-XON-1874-v1 | September 2025